Albireo to Report Q2 2020 Financial Results on August 6

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO) announced a conference call on August 6, 2020, at 10:00 a.m. ET to discuss its Q2 2020 financial results and business updates. The company is developing bile acid modulators for pediatric liver diseases, with its lead candidate odevixibat in Phase 3 trials for progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. Another candidate, elobixibat, is in Phase 2 for NAFLD and NASH, and is already approved in Japan for chronic constipation. Albireo operates from Boston and is recognized as one of Massachusetts' Best Places to Work.

Positive

• Odevixibat is in Phase 3 trials for PFIC and biliary atresia, indicating significant progress in drug development.
• Elobixibat is approved in Japan, showcasing the company's ability to successfully launch products.

Negative

• None.

— Conference call and webcast to be held at 10:00 a.m. ET — 

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 6, 2020, to provide a business update and review the company’s financial results for the second quarter ended June 30, 2020.

To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13706144. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.

Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568
Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com

FAQ

What is the date and time of Albireo Pharma's next conference call?

Albireo Pharma's next conference call is scheduled for August 6, 2020, at 10:00 a.m. ET.

What are the main products in Albireo Pharma's pipeline?

Albireo Pharma's main products include odevixibat, in Phase 3 for PFIC and biliary atresia, and elobixibat, in Phase 2 for NAFLD and NASH.

When will Albireo Pharma release its Q2 2020 financial results?

Albireo Pharma will release its Q2 2020 financial results during the conference call on August 6, 2020.

Where can I access the Albireo Pharma conference call?

The Albireo Pharma conference call can be accessed by phone or through a live audio webcast on the company's website.